Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
FDMTthis company4D Molecular Therapeutics, Inc.	$12.59	-3.1×	0.86×	5.1×	-2.99×	-184.8%	91.1%	-187.2%	-164.4%	-27.7%	-30.2%	-25.1%	0.04×	0.29×	0×	9.39×	0.0%	3	1.71	2	C
ABEOAbeona Therapeutics Inc.	$2.80	3.93×	1.75×	47.95×	2.87×	-76.4%	73.7%	-1536.9%	1223.1%	44.7%	-44.0%	-30.2%	0.16×	-0.68×	-23.92×	6.93×	0.0%	2	-3.55	2	C
LXEOLexeo Therapeutics, Inc. Common Stock	$3.09	-5.34×	2.16×	0×	-4.89×	-69.1%	0.0%	0.0%	0.0%	-40.5%	-42.9%	-18.6%	0.03×	0.56×	-530.37×	11.21×	0.0%	1	5.08	2	B-
MGTXMeiraGTx Holdings plc	$9.40	-5.6×	-110.38×	7.86×	-7.4×	-554.4%	94.0%	-130.2%	-140.3%	1971.4%	-70.9%	-7.8%	-15.31×	-0.25×	-8.69×	0.75×	0.0%	6	4.07	3	B
OCGNOcugen, Inc.	$0.96	-5.87×	-33.31×	91.83×	-6.97×	-126.5%	45.9%	-1425.7%	-1537.4%	557.7%	-278.6%	-14.1%	-2.72×	-0.24×	-12.13×	1.06×	0.0%	2	-6.2	2	C
RGNXREGENXBIO Inc.	$7.90	-3.83×	7.23×	4.36×	-7.27×	-438.7%	88.1%	-94.6%	-113.8%	-188.7%	-42.1%	-17.0%	2.54×	-1.7×	-3.58×	2.38×	0.0%	2	-3.81	1	D+
Peer median	—	-5.34×	1.75×	7.86×	-6.97×	-126.5%	73.7%	-130.2%	-113.8%	44.7%	-44.0%	-17.0%	0.03×	-0.25×	-12.13×	2.38×	0.0%	2	-3.55	2	—